Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Bicara Therapeutics, Inc. (BCAX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.19-7.87%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BCAX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund operations into first half of 2029 | Bicara Therapeutics aims to fund operations into the first half of 2029. | Intact | Cash reserves fall below levels needed to fund operations into H1 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology business, not a proven earnings compounder. Its long-term thesis is in a watch state: management is advancing key studies, but recent financial performance is weak and confidence in the evidence is low.
The snapshot provides no valuation level or specific market expectations, so whether BCAX is cheap, fair, or expensive versus peers cannot be assessed. It reports low valuation fragility, but that does not establish what clinical or earnings progress the market already assumes.
Near term, earnings risk is elevated after a recent miss and a run of misses; another guidance cut would add concern. Over the multi-year view, trial progress is tangible: the pivotal FORTIFI-HN01 study is on track for substantial enrollment by year-end 2026, and a randomized dosing study began in Q3 2026. Higher research spending reflects that work, while clinical-response evidence and commercial prospects remain uncertain.
The thesis depends on continued trial execution and whether follow-up data support deep, durable responses with ficerafusp alfa. Near-term setbacks could come from lower guidance or worsening employment data, while stronger results and guidance from major healthcare companies could support the sector backdrop. The snapshot gives limited evidence on the recent material agreement, so its effect on the thesis is unclear.
Over the next 1 to 3 years, BCAX remains a high-risk clinical-development story: trial progress supports the thesis, but weak financial performance and elevated earnings risk leave important proof points ahead. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Bicara Therapeutics, Inc.'s published investment case. The stated target is No further significant insider share sales by CEO or key executives. |
| Under Pressure |
| Additional significant insider sales by CEO or key executives |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating losses | Management focuses on controlling operating losses, though losses grew from -$32.0M in 2025-Q2 to -$60.2M in 2026-Q1. | Under Pressure | Operating losses worsen beyond -$60.2M per quarter | Operating income: $-59.951M FY2026-Q2; GAAP. Published target: Operating losses do not worsen beyond -$60.2M per quarter. Target period is not explicitly aligned with this observation. Aug 11, 2026-59,951,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.70 → $-3.62 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.70 | Unavailable | 10 / 0 |
| 2026-07-25 | $-3.70 | Unavailable | 10 / 0 |
| 2026-07-26 | $-3.70 | Unavailable | 10 / 0 |
| 2026-07-27 | $-3.70 | Unavailable | 10 / 0 |
| 2026-07-28 | $-3.63 | $0 | 12 / 12 |
| 2026-07-29 | $-3.63 | $0 | 12 / 12 |
| 2026-07-30 | $-3.63 | $0 | 12 / 12 |
| 2026-07-31 | $-3.63 | $0 | 12 / 12 |
| 2026-08-01 | $-3.63 | $0 | 12 / 12 |
| 2026-08-02 | $-3.63 | $0 | 12 / 12 |
| 2026-08-03 | $-3.63 | $0 | 12 / 12 |
| 2026-08-04 | $-3.63 | $0 | 12 / 12 |
| 2026-08-05 | $-3.63 | $0 | 12 / 12 |
| 2026-08-06 | $-3.63 | $0 | 12 / 12 |
| 2026-08-07 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-08 | $-3.63 | $0 | 12 / 12 |
| 2026-08-09 | $-3.63 | $0 | 12 / 12 |
| 2026-08-10 | $-3.63 | $0 | 12 / 12 |
| 2026-08-11 | $-3.63 | $0 | 12 / 12 |
| 2026-08-12 | $-3.61 | $0 | 12 / 11 |
| 2026-08-13 | $-3.61 | $0 | 12 / 11 |
| 2026-08-14 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-15 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-16 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-17 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-18 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-19 | $-3.70 | Unavailable | 10 / 0 |
| 2026-08-20 | $-3.55 | Unavailable | 11 / 0 |
| 2026-08-21 | $-3.55 | Unavailable | 11 / 0 |
| 2026-08-22 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-23 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-24 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-25 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-26 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-27 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-28 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-29 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-30 | $-3.52 | Unavailable | 11 / 0 |
| 2026-08-31 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-01 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-02 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-03 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-04 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-05 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-06 | $-3.52 | Unavailable | 11 / 0 |
| 2026-09-07 | $-3.52 | Unavailable | 10 / 0 |
| 2026-09-08 | $-3.52 | Unavailable | 10 / 0 |
| 2026-09-09 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-10 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-11 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-12 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-13 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-14 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-15 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-16 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-17 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-18 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-19 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-20 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-21 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-22 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-23 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-24 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-25 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-26 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-27 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-28 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-29 | $-3.56 | Unavailable | 10 / 0 |
| 2026-09-30 | $-3.56 | Unavailable | 10 / 0 |
| 2026-10-01 | $-3.56 | Unavailable | 9 / 0 |
| 2026-10-02 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-03 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-04 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-05 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-06 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-07 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-08 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-09 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-10 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-11 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-12 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-13 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-14 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-15 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-16 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-17 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-18 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-19 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-20 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-21 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-22 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-23 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-24 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-25 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-26 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-27 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-28 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-29 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-30 | $-3.62 | Unavailable | 9 / 0 |
| 2026-10-31 | $-3.62 | Unavailable | 9 / 0 |
| 2026-11-01 | $-3.62 | Unavailable | 9 / 0 |
| 2026-11-02 | $-3.62 | Unavailable | 9 / 0 |
| 2026-11-03 | $-3.62 | Unavailable | 9 / 0 |
| 2026-11-04 | $-3.62 | Unavailable | 9 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.